

INFECTION MEDICINES

MARKETED PRODUCTS

Synagis (palivizumab) is a humanised monoclonal antibody (MAb) for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in paediatric patients at high risk of acquiring RSV disease (pneumonia and bronchiolitis).

Merrem/Meronem¹ (meropenem) is an intravenous carbapenem anti-bacterial for the treatment of serious, hospital-acquired infections.

FluMist (influenza virus vaccine live, intranasal) is a live, attenuated vaccine for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, two to 17 years of age, and healthy adults, 18 to 49 years of age.

2007 IN BRIEF

- > **Merrem sales of \$773 million, up 20%.**
- > **Steady underlying growth for Merrem in the US (32%) and in Western Europe (20%).**
- > **Since the acquisition of MedImmune in June, Synagis sales of \$618 million and FluMist sales of \$53 million.**
- > **Acquisition of Arrow Therapeutics has added anti-viral capability.**
- > **Acquisition of MedImmune has added infection-focused monoclonal antibody and vaccine technology.**
- > **Work dedicated to finding a new treatment for tuberculosis continues at our R&D facility in Bangalore, India.**

¹ Licensed from Dainippon Sumitomo Pharma Co., Ltd.

PERFORMANCE

	2007			2006			2005	2007 compared to 2006		2006 compared to 2005	
	Sales \$m	Growth underlying \$m	due to exchange effects \$m	Sales \$m	Growth underlying \$m	due to exchange effects \$m		Growth underlying %	Growth reported %	Growth underlying %	Growth reported %
Merrem/Meronem	773	121	48	604	96	3	505	20	28	19	20
Synagis ²	618	618	–	–	–	–	–	n/m	n/m	n/m	n/m
FluMist ²	53	53	–	–	–	–	–	n/m	n/m	n/m	n/m
Other	270	(12)	11	271	(59)	(4)	334	(4)	–	(18)	(19)
Total	1,714	780	59	875	37	(1)	839	89	96	4	4

² Sales of these MedImmune products are consolidated in AstraZeneca accounts from 1 June 2007. As a result, there are no prior period sales included.

PIPELINE

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date	
			I	II	III	Europe	US
NCEs							
Motavizumab (MedImmune)	humanised monoclonal antibody	RSV prevention	■	■	■	1H 2009	Filed
CytoFab™	anti-TNF-alpha polyclonal antibody	severe sepsis	■	■			
EBV vaccine ³	Epstein-Barr virus vaccine	post-transplant proliferative disease	■	■			
AZD2836	5a replicon	hepatitis C	■	■			
MEDI-524 (motavizumab)	MAb targets F-protein	early and late treatment of disease in infants >1 yr	■	■			
MEDI-534	RSV/PIV-3 vaccine	intranasal immunisation	■				
MEDI-560	PIV-3 vaccine	intranasal immunisation	■				
H5N1	H5N1 influenza virus vaccine	pandemic influenza vaccine	■				
MEDI-564	F-protein inhibitor	RSV treatment	■				
CMV vaccine	CMV vaccine	cytomegalovirus	■				
MEDI-557	YTE – extended half-life RSV MAb	RSV prophylaxis	■				
Line extensions							
FluMist (MedImmune)	live, attenuated, intranasal influenza virus vaccine	influenza	■	■	■	2Q 2008	Launched

³ Partnered product.

For discontinued projects see page 30.